Evaluation of a Pharmacokinetic Interaction between Telmisartan and Chlorthalidone in Healthy Male Adult Subjects-Reference-Cited by-同舟云学术

Evaluation of a Pharmacokinetic Interaction between Telmisartan and Chlorthalidone in Healthy Male Adult Subjects

Published:2016-05-20 Issue:8 Volume:36 Page:613-623
ISSN:1173-2563
Container-title:Clinical Drug Investigation
language:en
Short-container-title:Clin Drug Investig

Author:

Seong Sook Jin,Lim Mi-sun,Lee Joomi,Ohk Boram,Gwon Mi-Ri,Kim Bo Kyung,Kim Hyun-Ju,Yang Dong Heon,Lee Hae Won,Kang Woo Youl,Yoon Young-Ran

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s40261-016-0406-y.pdf

Reference25 articles.

1. Maillard MP, Burnier M. Is the fixed-dose combination of telmisartan and hydrochlorothiazide a good approach to treat hypertension? Vascular Health Risk Manage. 2007;3(3):265–78.

2. Keating GM. Losartan/hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy. Drugs. 2009;69(9):1239–65.

3. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs. 2001;61(10):1501–29.

4. Karlberg BE, Lins L-E, Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. J Hypertension. 1999;17:293–302.

5. Freytag F, Schelling A, Meinicke T, Deichsel G, for the Telmisartan Hypertension Experience in a Randomized European Study Versus Atenolol Study Group. Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. Clin Ther. 2001;23(1):108–23.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progress in Quantitative Methods for Azelnidipine and Chlorthalidone: An Analytical Basis for a Recently Approved FDC;Current Pharmaceutical Analysis;2023-01